Daniel Carlson

2062 POSTS 639 COMMENTS

Front Page

INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development...

Daniel Carlson - February 8, 2023

Front Page

Trading Update, February 8th 2023

Daniel Carlson - February 8, 2023

Front Page

Double Trouble

Daniel Carlson - February 3, 2023

Front Page

Spectra7 to Showcase 200 and 400Gbps Connectivity using Active Copper Cables...

Daniel Carlson - February 3, 2023

Front Page

Awaiting Liftoff…Catalyst List

Daniel Carlson - January 27, 2023

Front Page

Trading Update, January 27th 2023

Daniel Carlson - January 27, 2023

Front Page

Movano Health Prices $6.5 Million Public Offering

Daniel Carlson - January 27, 2023

Front Page

INmune in DMD…Yet Another Indication of Future Success

Daniel Carlson - January 25, 2023

Front Page

INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach...

Daniel Carlson - January 25, 2023

Front Page

Looking for 3-5X This Year? These Two Jackpot Stocks Offer That...

Daniel Carlson - January 21, 2023

Front Page

Spectra7 Announces Preliminary Fourth Quarter and Annual Financial Results for the...

Daniel Carlson - January 18, 2023

enVVeno

enVVeno Medical Promotes Dr. Hamed Alavi to Senior Vice President and...

Daniel Carlson - January 18, 2023

Front Page

Notes for Premium Subscribers

Daniel Carlson - January 17, 2023

Front Page

Lantern Pharma Receives Pre-IND Feedback from the FDA, Clearing a Path...

Daniel Carlson - January 17, 2023

Front Page

The January Halftime Report

Daniel Carlson - January 14, 2023

Front Page

The 2023 Game Plan

Daniel Carlson - January 10, 2023

Front Page

Spectra7, ACON, and Mo-Link to Demonstrate Thunderbolt 4 Active Copper Cables...

Daniel Carlson - January 10, 2023

Front Page

TFF Pharmaceuticals Announces the Appointment of Zamaneh Mikhak, M.D. as Chief...

Daniel Carlson - January 9, 2023

Front Page

For The TW Portfolio, Our FATE Awaits

Daniel Carlson - January 7, 2023

Uncategorized

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284...

Daniel Carlson - January 5, 2023

Front Page

IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals

Daniel Carlson - January 5, 2023

Front Page

IN8bio to Present at Biotech Showcase 2023 in San Francisco

Daniel Carlson - January 3, 2023

Front Page

The Light at the End of the Tunnel

Daniel Carlson - December 31, 2022

Front Page

Trading Thoughts As We Prepare To Swap Out The Calendar

Daniel Carlson - December 29, 2022

Front Page

Movano Health Unveils Evie: First Medical Grade Smart Ring Designed Uniquely...

Daniel Carlson - December 28, 2022

Front Page

Trading Alert: Initiating a New Position

Daniel Carlson - December 19, 2022

Front Page

Holiday Cheers!

Daniel Carlson - December 17, 2022

Front Page

Movano Health On Track to File First FDA Submission for its...

Daniel Carlson - December 15, 2022

Front Page

Movano Health Announces Launch of Smart Ring Beta Program with Novant...

Daniel Carlson - December 15, 2022

Front Page

Lantern Pharma Announces Development of Drug Candidate LP-184 for Triple Negative...

Daniel Carlson - December 15, 2022

Front Page

Lantern Pharma Announces Positive New Data for its Drug Candidate LP-284...

Daniel Carlson - December 15, 2022

Front Page

Santa Claus Ain’t Coming To Town

Daniel Carlson - December 10, 2022

Anixa

Anixa Biosciences Announces Maximum Tolerated Dose Reached in Trial of Preventative...

Daniel Carlson - December 8, 2022

Front Page

INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell...

Daniel Carlson - December 8, 2022

Front Page

INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to...

Daniel Carlson - December 6, 2022

Front Page

TFF Pharmaceuticals Announces Leadership Transition

Daniel Carlson - December 5, 2022

Front Page

Informed Decisions

Daniel Carlson - December 3, 2022

Front Page

Spectra7 Announces Third Quarter 2022 Financial Results

Daniel Carlson - December 3, 2022

Front Page

INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance...

Daniel Carlson - November 29, 2022

Front Page

Pardon Me

Daniel Carlson - November 26, 2022

Front Page

Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug...

Daniel Carlson - November 22, 2022

Front Page

Pot Watching…

Daniel Carlson - November 19, 2022

Front Page

TFF Pharmaceuticals Prices $10.675 Million Offering of Common Stock and Warrants

Daniel Carlson - November 18, 2022

Front Page

Trading Blog, November 17, 2022

Daniel Carlson - November 17, 2022

Front Page

Positive 3-Year VenoValve® First-in-Human Data Presented at 49th Annual VEITH Symposium...

Daniel Carlson - November 17, 2022

Front Page

Trading Blog, November 16, 2022

Daniel Carlson - November 16, 2022

Front Page

INmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence...

Daniel Carlson - November 14, 2022

Front Page

Crashing Bitcoins and Other Thoughts

Daniel Carlson - November 12, 2022

Anixa

Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the...

Daniel Carlson - November 9, 2022

Front Page

enVVeno Medical Successfully Passes Preliminary FDA Safety Review for the VenoValve...

Daniel Carlson - November 7, 2022

Front Page

Dinner Table Talk

Daniel Carlson - November 5, 2022

Front Page

ParkerVision Secures Patent License Agreement with Hisense

Daniel Carlson - November 3, 2022

Front Page

TFF Pharmaceuticals Announces Collaboration with Aptar Pharma to Explore and Develop...

Daniel Carlson - November 3, 2022

Front Page

TFF Delays Data and Other Thoughts Heading Into Year-End 2022

Daniel Carlson - November 2, 2022

Front Page

TFF Pharmaceuticals Announces Program Updates for Voriconazole Inhaled Powder and Tacrolimus...

Daniel Carlson - November 1, 2022

Front Page

TFF Pharmaceuticals Announces Second Patient Successfully Treated with Voriconazole Inhalation Powder...

Daniel Carlson - November 1, 2022

Front Page

Sanford M. Litvack Joins ParkerVision Board of Directors

Daniel Carlson - November 1, 2022

Anixa

Dr. Jose Conejo-Garcia, Invited to Present Keynote Address at Duke Cancer...

Daniel Carlson - October 31, 2022

Front Page

Counting Down to Catalysts

Daniel Carlson - October 29, 2022

Front Page

Spectra7 Announces Return of Chief Executive Officer Raouf Halim to Half...

Daniel Carlson - October 29, 2022

Front Page

enVVeno Medical Reports Third Quarter 2022 Financial Results and Provides Corporate...

Daniel Carlson - October 28, 2022

Anixa

Anixa Biosciences Announces Commencement of Phase 1b Trial of its Breast...

Daniel Carlson - October 26, 2022

Front Page

Keeping An Eye On The Trees

Daniel Carlson - October 22, 2022

Front Page

Lantern Pharma Announces Issuance of New Patent that Strengthens Patent Portfolio...

Daniel Carlson - October 20, 2022

Front Page

INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple...

Daniel Carlson - October 19, 2022

Front Page

Resetting Expectations

Daniel Carlson - October 15, 2022

Front Page

Spectra7 Announces Preliminary Third Quarter 2022 Revenue and Second Half 2022...

Daniel Carlson - October 15, 2022

Front Page

TFF Pharmaceuticals Announces Presentation of Data Featuring Applications of Thin Film...

Daniel Carlson - October 11, 2022

Anixa

Anixa Biosciences Announces Presentation on Ovarian Cancer CAR-T Therapy Trial at...

Daniel Carlson - October 10, 2022

Front Page

Bringing Down the House

Daniel Carlson - October 8, 2022

Front Page

Welcome Back???

Daniel Carlson - October 1, 2022

Front Page

enVVeno Medical Announces the Development of a Transcatheter Based Replacement Venous...

Daniel Carlson - September 27, 2022

Front Page

Trading Alert, Sept. 15th, 2022

Daniel Carlson - September 15, 2022

Front Page

Lantern Pharma to Present Positive Preclinical Data on the Efficacy of...

Daniel Carlson - September 14, 2022

Anixa

Anixa Biosciences’ Ovarian Cancer CAR-T Therapy to be Presented at the...

Daniel Carlson - September 12, 2022

Front Page

Moving Day

Daniel Carlson - September 10, 2022

Front Page

TFF Pharmaceuticals Announces Presentation of Patient Data with Voriconazole Inhalation Powder...

Daniel Carlson - September 8, 2022

Front Page

Don’t Fight The FED. TW’s August Recap.

Daniel Carlson - September 3, 2022

Front Page

The Bear Returns

Daniel Carlson - August 27, 2022

Uncategorized

Spectra7 Announces Closing of the Upsized Convertible Debenture Financing of $8.9...

Daniel Carlson - August 27, 2022

Front Page

Spectra7 Announces Upsizing of Convertible Debenture Financing to $9.0 Million

Daniel Carlson - August 23, 2022

Front Page

When News Is Good

Daniel Carlson - August 20, 2022

Front Page

Trading Alert, August 18th, 2022

Daniel Carlson - August 18, 2022

Front Page

enVVeno Medical Appoints Kevin Belteau as Vice President of Clinical Operations

Daniel Carlson - August 16, 2022

Anixa

CAR-T Trial Launches…An Interview With Dr. Amit Kumar, CEO of Anixa

Daniel Carlson - August 15, 2022

Anixa

Anixa Biosciences Announces Treatment of First Patient in its Ovarian Cancer...

Daniel Carlson - August 15, 2022

Front Page

Pendulum Swings

Daniel Carlson - August 13, 2022

Front Page

Movano Expands Go-To-Market Team with Vice President of UX and UI...

Daniel Carlson - August 12, 2022

Front Page

Movano Ring Exceeds Accuracy Targets for SpO2 and Heart Rate Monitoring...

Daniel Carlson - August 9, 2022

Front Page

The Domino Effect

Daniel Carlson - August 6, 2022

Front Page

Trading Alert, August 5th, 2022

Daniel Carlson - August 5, 2022

Front Page

Trading Alert, August 2nd, 2022

Daniel Carlson - August 2, 2022

Front Page

Micros Rallied in July, Can It Continue?

Daniel Carlson - July 30, 2022

Front Page

Spectra7 Announces $8.0 Million Convertible Debenture Financing; Closing of First Tranche

Daniel Carlson - July 27, 2022

Fortress Bio

Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral...

Daniel Carlson - July 27, 2022

Uncategorized

INmune Bio, Inc. CEO, Raymond J. Tesi, MD, to Participate in...

Daniel Carlson - July 25, 2022

Front Page

Dog Days of Summer

Daniel Carlson - July 23, 2022

Anixa

Anixa Biosciences Announces Notice of Allowance of Additional Patent on Breast...

Daniel Carlson - July 21, 2022

Front Page

Trading Alert, July 19th, 2022

Daniel Carlson - July 19, 2022

Front Page

Taking the Long View on TFF

Daniel Carlson - July 16, 2022

Front Page

TFF Pharmaceuticals Expands R&D Operations with New Austin Facility

Daniel Carlson - July 14, 2022

Front Page

Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical...

Daniel Carlson - July 14, 2022

Front Page

Catalysts Aplenty, a 2nd Half Preview

Daniel Carlson - July 9, 2022

Front Page

Texas Court Grants ParkerVision Motion to Add Willfulness to Intel Complaint

Daniel Carlson - July 8, 2022

Front Page

enVVeno Medical Announces the Issuance of a New Unique Category III...

Daniel Carlson - July 8, 2022

Amryt

Amryt Presents New Analyses from the EASE Phase 3 Trial in...

Daniel Carlson - July 7, 2022

Front Page

June in Review

Daniel Carlson - July 1, 2022

Front Page

This Week’s Newsletter

Daniel Carlson - June 25, 2022

Amryt

European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional...

Daniel Carlson - June 23, 2022

Front Page

Spectra7 Expands Availability of Active Copper Cables with new Design-in with...

Daniel Carlson - June 23, 2022

Front Page

USPTO Issues Patent Covering Use of XPro™ for Treatment of CNS...

Daniel Carlson - June 22, 2022

Anixa

Anixa Biosciences Announces Publication of Peer-Reviewed Journal Article in Clinical and...

Daniel Carlson - June 21, 2022

Anixa

Going Downhill

Daniel Carlson - June 18, 2022

Front Page

INmune Bio, Inc. Presents Data on Combination Therapy with INB03™ on...

Daniel Carlson - June 16, 2022

Amryt

Amryt Presents Data for Mycapssa® (oral octreotide) from OPTIMAL and MPOWERED...

Daniel Carlson - June 13, 2022

Anixa

High Degree of Confidence

Daniel Carlson - June 9, 2022

Amryt

Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials...

Daniel Carlson - June 8, 2022

Atomera

June Gloom

Daniel Carlson - June 4, 2022

Fortress Bio

Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial...

Daniel Carlson - May 31, 2022

Front Page

Spectra7 Announces First Quarter 2022 Financial Results

Daniel Carlson - May 31, 2022

Front Page

Establishing Lows

Daniel Carlson - May 28, 2022

Front Page

INMB: Making Sense of The FDA Clinical Hold

Daniel Carlson - May 25, 2022

Front Page

INmune Bio, Inc. to Provide Additional Manufacturing Information to FDA as...

Daniel Carlson - May 23, 2022

Anixa

CEO Knows Best

Daniel Carlson - May 21, 2022

Fortress Bio

Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency...

Daniel Carlson - May 19, 2022

Front Page

Quest Resource Holding Corporation Reports First Quarter 2022 Financial Results

Daniel Carlson - May 16, 2022

Front Page

INmune Bio Looks to Change The CNS Landscape

Daniel Carlson - May 16, 2022

Front Page

It’s Still The Early Innings

Daniel Carlson - May 14, 2022

Front Page

Movano Successfully Completes Functional Testing of Smallest Ever Custom mmWave Sensor...

Daniel Carlson - May 13, 2022

Front Page

TFF Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business...

Daniel Carlson - May 11, 2022

Front Page

INmune Bio, Inc. Presents Data Demonstrating XPro™ Promotes Remyelination in Gray...

Daniel Carlson - May 10, 2022

Anixa

Stepping on Rakes

Daniel Carlson - May 7, 2022

Front Page

INmune Bio, Inc. Announces First Quarter 2022 Results and Provides Business...

Daniel Carlson - May 5, 2022

Front Page

Top Global Virtual Reality Gaming Company Chooses Spectra7 Chipset to Power...

Daniel Carlson - May 5, 2022

Front Page

enVVeno Medical Reports First Quarter 2022 Financial Results and Provides Corporate...

Daniel Carlson - May 2, 2022

Front Page

TFF Pharmaceuticals Announces Multiple Presentations Highlighting Broad Applicability of its Thin...

Daniel Carlson - May 2, 2022

Front Page

Spectra7 Announces Fourth Quarter and Fiscal Year 2021 Financial Results

Daniel Carlson - May 2, 2022

Anixa

The Rolling Correction Gathers Steam…

Daniel Carlson - April 30, 2022

Anixa

Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the...

Daniel Carlson - April 28, 2022

Atomera

Atomera Provides First Quarter 2022 Results

Daniel Carlson - April 27, 2022

Atomera

Atomera Enters into Joint Development Agreement with Major Foundry

Daniel Carlson - April 27, 2022

Front Page

Does Nkarta’s Positive NK Data Have Any Relation To INmune Bio’s...

Daniel Carlson - April 25, 2022

$Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106, CD20-Targeted CAR T Therapy, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia$

Fortress Bio

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106, CD20-Targeted...

Daniel Carlson - April 25, 2022

Amryt

It’s A Process

Daniel Carlson - April 23, 2022

Amryt

CHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic...

Daniel Carlson - April 22, 2022

Front Page

TFF Announces Data from Phase 1 Study of Niclosamide

Daniel Carlson - April 19, 2022

Front Page

Movano Hires Chief Marketing Officer to Implement Its Multi-Channel Marketing Strategy...

Daniel Carlson - April 18, 2022

Company

How’s Your Balance (Sheet)?

Daniel Carlson - April 16, 2022

Atomera

Atomera Successfully Meets Requirements of Joint Development Agreement

Daniel Carlson - April 14, 2022

Front Page

INmune Bio Announces First Patient Dosed in Phase 2 XPro1595 Trial...

Daniel Carlson - April 13, 2022

Amryt

Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa® (oral...

Daniel Carlson - April 13, 2022

Front Page

INmune Bio, Inc. to Present Preclinical Data on INB03 at the...

Daniel Carlson - April 12, 2022

Front Page

Your Home Is Worth What???

Daniel Carlson - April 9, 2022

Anixa

Anixa Zoom Recap

Daniel Carlson - April 7, 2022

Front Page

Spectra7 Announces Preliminary First Quarter 2022 Revenue and Provides Business Update

Daniel Carlson - April 7, 2022

Anixa

Anixa Biosciences’ Ovarian Cancer CAR-T Therapy to be Discussed at The...

Daniel Carlson - April 6, 2022

Front Page

All Coming Together

Daniel Carlson - April 5, 2022

Front Page

INmune Bio, Inc. Highlights INKmune™ Data Featured in NK Cells in...

Daniel Carlson - April 4, 2022

Front Page

The New Reality

Daniel Carlson - April 2, 2022

Anixa

Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase...

Daniel Carlson - March 30, 2022

Front Page

Spectra7 Partners with Volex to Deliver Next Generation 800Gbps Data Center...

Daniel Carlson - March 30, 2022

Front Page

INmune Bio, Inc. Announces Company’s CSO Dr. Mark Lowdell to Co-Host...

Daniel Carlson - March 30, 2022

Front Page

enVVeno Medical Reports Fourth Quarter and Year-End 2021 Financial Results and...

Daniel Carlson - March 28, 2022

Front Page

Separating the Wheat From the Chaff

Daniel Carlson - March 26, 2022

Front Page

INmune Bio, Inc. Spotlights Key Findings in Presentations at AD/PD™ 2022

Daniel Carlson - March 25, 2022

Front Page

Movano Inc. Provides Business Update and Reports Fourth Quarter 2021 Financial...

Daniel Carlson - March 25, 2022

Front Page

TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results...

Daniel Carlson - March 24, 2022

Front Page

Update on INmune, TFF Pharma and DarioHealth

Daniel Carlson - March 24, 2022

Fortress Bio

Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce CUTX-101, Copper Histidinate,...

Daniel Carlson - March 21, 2022

Front Page

Buy The Rumor, Sell The News

Daniel Carlson - March 19, 2022

Front Page

For Those Looking To Play A Bounce, Here’s A Candidate

Daniel Carlson - March 18, 2022

Front Page

TFF Pharmaceuticals Enters into CRADA with the U.S. Army and The...

Daniel Carlson - March 17, 2022

Front Page

INmune Bio, Inc. Announces Nine Data Presentations at AD/PD™ 2022 –...

Daniel Carlson - March 15, 2022

Anixa

Groundhog Day

Daniel Carlson - March 12, 2022

Front Page

Orlando Court Grants Qualcomm Motion Blocking ParkerVision’s Presentation of Key Evidence...

Daniel Carlson - March 11, 2022

Front Page

QUEST RESOURCE HOLDING CORPORATION ANNOUNCES STRONG PRELIMINARY FOURTH QUARTER 2021 FINANCIAL...

Daniel Carlson - March 10, 2022

Anixa

ANIX Update

Daniel Carlson - March 9, 2022

Front Page

One-Year VenoValve(R) Data Published in Peer-Reviewed Journal, Vascular and Endovascular Surgery

Daniel Carlson - March 9, 2022

Amryt

Amryt Announces 22% growth in FY 2021 Revenues to $222.5M

Daniel Carlson - March 9, 2022

Amryt

Amryt Announces Successful Bioavailability Study for Mycapssa® (octreotide capsules)

Daniel Carlson - March 8, 2022

Front Page

This Trend is NOT Your Friend

Daniel Carlson - March 5, 2022

Front Page

INmune, a very brief update

Daniel Carlson - March 4, 2022

Atomera

Atomera’s Enhanced MSTcad Helps Chip Companies Quickly Realize MST Benefits

Daniel Carlson - March 3, 2022

Front Page

TFF Pharmaceuticals and Catalent Announce New Inhalation Dry Powder Development and...

Daniel Carlson - March 1, 2022

Front Page

TFFP: More Thoughts Regarding NICLOSAMIDE

Daniel Carlson - February 28, 2022

Amryt

Amryt Receives Complete Response Letter from the FDA for Oleogel-S10 NDA

Daniel Carlson - February 28, 2022

Amryt

Putin It In Perspective

Daniel Carlson - February 25, 2022

Front Page

Positive Long-Term VenoValve® First-in-Human Data Presented at 34th Annual Meeting of...

Daniel Carlson - February 25, 2022

Front Page

TFF Pharmaceuticals Announces Inhaled Niclosamide Significantly Inhibits Viral Replication of the...

Daniel Carlson - February 24, 2022

Front Page

Good News

Daniel Carlson - February 19, 2022

Front Page

enVVeno Medical Announces ISO 13485 Certification

Daniel Carlson - February 19, 2022

Front Page

Updating My Thinking On INmune (INMB) and TFF Pharma (TFFP)

Daniel Carlson - February 18, 2022

Front Page

Movano Completes its Second Glucose Pilot Study

Daniel Carlson - February 18, 2022

Front Page

Movano Announces Two Key Hires to Further Its Go-To-Market Strategy for...

Daniel Carlson - February 15, 2022

Atomera

End Game

Daniel Carlson - February 12, 2022

Atomera

Quest and Atomera Spike…Should You Be A Buyer?

Daniel Carlson - February 10, 2022

Atomera

Atomera Licenses MST® Technology to Semiconductor Foundry

Daniel Carlson - February 8, 2022

Front Page

Updates From Several Management Calls

Daniel Carlson - February 6, 2022

Atomera

Metamorphosis

Daniel Carlson - February 5, 2022

Front Page

This Week’s Billboard Headline…Glenn Mattes Stars As Rocky Balboa!

Daniel Carlson - January 29, 2022

Amryt

Amryt Announces Oleogel-S10 EMA Regulatory Update

Daniel Carlson - January 28, 2022

Front Page

Spectra7: Hyper-Growth in Hyper-Scale Data Centers

Daniel Carlson - January 27, 2022

Front Page

TFF Pharmaceuticals Completes Enrollment in Phase 1 Study Evaluating Inhaled Formulation...

Daniel Carlson - January 27, 2022

Front Page

INmune Bio, Inc. Announces Research Collaboration with Chinese University of Hong...

Daniel Carlson - January 25, 2022

Fortress Bio

Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of...

Daniel Carlson - January 25, 2022

Front Page

PTAB Issues Rulings in ParkerVision IPRs Filed by Intel

Daniel Carlson - January 25, 2022

Front Page

Spectra7 Announces Preliminary Fourth Quarter 2021 Revenue and Record Order Backlog...

Daniel Carlson - January 24, 2022

Front Page

Lantern Pharma Receives Rare Pediatric Disease and Orpan Drug Designations for...

Daniel Carlson - January 24, 2022

Anixa

Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease...

Daniel Carlson - January 24, 2022

Front Page

Welcome To The Terrordome

Daniel Carlson - January 22, 2022

Front Page

An INKmune Update, Catalysts Included…

Daniel Carlson - January 17, 2022

Anixa

ParkerVision’s Time is Nigh…

Daniel Carlson - January 15, 2022

Front Page

Lantern Pharma Expands Precision Oncology Collaboration with the National Cancer Institute...

Daniel Carlson - January 13, 2022

Fortress Bio

Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule...

Daniel Carlson - January 13, 2022

Amryt

Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role...

Daniel Carlson - January 11, 2022

Anixa

Welcome to 2022?

Daniel Carlson - January 8, 2022

Front Page

Movano Completes Blood Pressure Study with 110 Participants

Daniel Carlson - January 3, 2022

Amryt

Happy New Year!!!

Daniel Carlson - January 1, 2022

Front Page

Movano Unveils Smart Ring Designed for Women Seeking More Approachable Health...

Daniel Carlson - December 27, 2021

Front Page

Trading Blog, December 22, 2021

Daniel Carlson - December 22, 2021

Front Page

TFF Pharmaceuticals Announces Final Data from Phase 1b Study of Inhaled...

Daniel Carlson - December 21, 2021

Front Page

Who Believes? Santa Rally Coming…

Daniel Carlson - December 18, 2021

Front Page

Lantern Pharma Presents Positive Data on the Effectiveness of LP-284 in...

Daniel Carlson - December 14, 2021

Front Page

No QUESTion, This Stock’s A Winner

Daniel Carlson - December 11, 2021

Front Page

INmune Bio, Inc. Announces Key Breast Cancer Treatment Resistance Data to...

Daniel Carlson - December 9, 2021

Front Page

Quest Resource Holding Acquires Two Asset-Light Waste Services Companies

Daniel Carlson - December 8, 2021

Anixa

Anixa Biosciences and MolGenie Announce that their COVID-19 Compounds are Expected...

Daniel Carlson - December 7, 2021

Fortress Bio

Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce the Initiation of...

Daniel Carlson - December 7, 2021

Front Page

TFF Pharmaceuticals Hosting Science Day on December 13, 2021

Daniel Carlson - December 6, 2021

Anixa

Bottom Picking

Daniel Carlson - December 4, 2021

Front Page

INmune Bio, Inc. Announces Two Presentations at the 2021 British Society...

Daniel Carlson - December 1, 2021

Atomera

Atomera Breathes New Life into Moore’s Law for Power and Analog...

Daniel Carlson - November 30, 2021

Front Page

Is OMICRON Potentially Positive For TFF Pharma?

Daniel Carlson - November 29, 2021

Fortress Bio

Avenue Therapeutics Announces FDA Advisory Committee Meeting to Review IV Tramadol...

Daniel Carlson - November 29, 2021

Anixa

Turkey Shoot…December Preview

Daniel Carlson - November 26, 2021

Front Page

Trading Blog, November 23rd, 2021

Daniel Carlson - November 23, 2021

Amryt

Amryt Provides Update on Regulatory Review Process for Oleogel-S10

Daniel Carlson - November 23, 2021

Amryt

Amryt Pharma plc Announces the Cancellation of Admission of its Ordinary...

Daniel Carlson - November 22, 2021

Front Page

Lantern Pharma Announces Share Repurchase Program

Daniel Carlson - November 22, 2021

Front Page

The Worst Bull Market Ever

Daniel Carlson - November 20, 2021

Front Page

Trading Blog, November 18th, 2021

Daniel Carlson - November 18, 2021

Atomera

Atomera Reaches 300 Patents Focused on Perfecting Atomic Level Engineering and...

Daniel Carlson - November 17, 2021

Front Page

Quest Resource Holding Corp. Reports 3rd Quarter 2021 Financial Results

Daniel Carlson - November 16, 2021

Fortress Bio

Fortress Biotech Reports Record Third Quarter 2021 Financial Results and Recent...

Daniel Carlson - November 16, 2021

Front Page

TFF Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business...

Daniel Carlson - November 16, 2021

Front Page

Three Non-Biotech Stocks

Daniel Carlson - November 12, 2021

Fortress Bio

Journey Medical Corporation Prices $35.2 Million Initial Public Offering

Daniel Carlson - November 12, 2021

Front Page

Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Glioblastoma Accepted...

Daniel Carlson - November 11, 2021

Front Page

enVVeno Medical Reports Third Quarter 2021 Financial Results and Provides Corporate...

Daniel Carlson - November 11, 2021

Front Page

QUEST RESOURCE HOLDING CORPORATION ACQUIRES ASSET-LIGHT WASTE SERVICES PROVIDER

Daniel Carlson - November 11, 2021

Front Page

Notes from INKmune Update

Daniel Carlson - November 10, 2021

Front Page

Trading Blog, November 9th, 2021

Daniel Carlson - November 9, 2021

Front Page

LexaGene Expands Bio-Pharma Contamination Panel by Adding Test that includes a...

Daniel Carlson - November 9, 2021

Front Page

TFF Pharmaceuticals Announces Completion of Dosing of Phase 1b Study for...

Daniel Carlson - November 8, 2021

Anixa

Asymmetric Risk

Daniel Carlson - November 6, 2021

Front Page

Lantern Pharma Announces Abstract on Effectiveness of LP-284 in Hematologic Cancers...

Daniel Carlson - November 4, 2021

Front Page

INmune Bio, Inc. Announces Third Quarter 2021 Results and Provides Business...

Daniel Carlson - November 3, 2021

Amryt

Amryt Reports Strong Q3 2021 Results

Daniel Carlson - November 3, 2021

Front Page

ParkerVision Receives Favorable Markman Recommendations in ParkerVision v. Hisense and TCL

Daniel Carlson - November 2, 2021

Front Page

Lantern Pharma Reports Third Quarter 2021 Financial Results and Operating Highlights

Daniel Carlson - November 1, 2021

Front Page

Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®,...

Daniel Carlson - November 1, 2021

Atomera

Trick or Treat? October Review

Daniel Carlson - October 30, 2021

Front Page

LexaGene Completes First Stage of U.S. ARMY DEVCOM Agreement

Daniel Carlson - October 29, 2021

Atomera

Atomera Provides Third Quarter 2021 Results

Daniel Carlson - October 28, 2021

Front Page

TFF Pharmaceuticals Receives Approval from Health Canada to Enter Human Clinical...

Daniel Carlson - October 28, 2021

Front Page

Code Ocean Selected by Lantern Pharma to Power A.I. and Computational...

Daniel Carlson - October 27, 2021

Front Page

INmune Bio, Inc. Announces Multiple Oral and Poster Presentations at the...

Daniel Carlson - October 27, 2021

Front Page

Trading Blog, October 26th, 2021

Daniel Carlson - October 26, 2021

Anixa

Anixa Biosciences Announces Patient Dosing of its Investigational Vaccine Candidate in...

Daniel Carlson - October 26, 2021

Front Page

LexaGene Completes Analytical Studies for FDA EUA of COVID-19 Testing

Daniel Carlson - October 25, 2021

Anixa

Training My Thoughts

Daniel Carlson - October 22, 2021

Front Page

enVVeno Medical Reports Successful Completion of First VenoValve Surgery for U.S....

Daniel Carlson - October 22, 2021

Amryt

Amryt Announces New Patents for Oleogel-S10 and Mycapssa®

Daniel Carlson - October 19, 2021

Anixa

Saturday Morning Musings

Daniel Carlson - October 16, 2021

Front Page

Why TFF’s Hamster Data Is Bigger Than Investors Think

Daniel Carlson - October 15, 2021

Front Page

Trading Blog, October 14th, 2021

Daniel Carlson - October 14, 2021

Front Page

TFF Pharmaceuticals and Augmenta Bioworks Publish Positive In Vivo Data Showing...

Daniel Carlson - October 14, 2021

Front Page

Ondas Holdings Inc. Announces Strategic Partnership with Dynam.AI

Daniel Carlson - October 11, 2021

Anixa

$8 Paddle Balls?

Daniel Carlson - October 9, 2021

Fortress Bio

Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101,...

Daniel Carlson - October 8, 2021

Front Page

LexaGene’s Largest Study Validates Accuracy of its Veterinary Test Panel

Daniel Carlson - October 7, 2021

Anixa

Anixa Biosciences Announces First Chinese Patent on its CAR-T Cancer Therapy...

Daniel Carlson - October 6, 2021

Front Page

Trading Blog, October 5th, 2021

Daniel Carlson - October 5, 2021

Amryt

October Awaits

Daniel Carlson - October 2, 2021

Anixa

Anixa Biosciences Announces Notice of Allowance for Additional Patent on its...

Daniel Carlson - October 1, 2021

Front Page

LexaGene Reports on Recent Veterinary Trade Shows

Daniel Carlson - September 30, 2021

Fortress Bio

Fortress Biotech Announces Receipt of Notice of Option Exercise from AstraZeneca...

Daniel Carlson - September 29, 2021

Front Page

Trading Blog, Sept. 28th, 2021

Daniel Carlson - September 28, 2021

Front Page

Lantern Pharma Enters into Strategic Collaboration with Deep Lens — Partnership...

Daniel Carlson - September 28, 2021

Front Page

Cash is King

Daniel Carlson - September 25, 2021

Front Page

TFF Pharmaceuticals Announces Promising Topline Results from Phase 1 Clinical Trial...

Daniel Carlson - September 23, 2021

Front Page

Trading Blog, Sept. 22nd, 2021

Daniel Carlson - September 22, 2021

Front Page

Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development...

Daniel Carlson - September 22, 2021

Front Page

Ondas Networks to Present at Annual Railway System Supplier Show

Daniel Carlson - September 22, 2021

Amryt

When The Tide Goes Out, You See Who’s Swimming Naked…

Daniel Carlson - September 18, 2021

Front Page

Trading Blog, Sept. 16th, 2021

Daniel Carlson - September 16, 2021

Front Page

Siemens Mobility to present Airlink Wireless Radio System in Live DemoCast

Daniel Carlson - September 16, 2021

Anixa

Anixa Biosciences’ Ovarian Cancer CAR-T Therapy to be Discussed at Upcoming...

Daniel Carlson - September 14, 2021

Amryt

Amryt Raises Full Year 2021 Revenue Guidance to $220M – $225M

Daniel Carlson - September 13, 2021

Front Page

Rolling Over? Markets Look Toppy To Me…

Daniel Carlson - September 11, 2021

Front Page

Trade Alert, Sept. 8, 2021

Daniel Carlson - September 8, 2021

Front Page

Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market...

Daniel Carlson - September 7, 2021

Anixa

Anixa Biosciences Appoints Dr. Pamela Garzone As Chief Development Officer

Daniel Carlson - September 7, 2021

Front Page

LexaGene’s MiQLab™ Accurately Detects Multiple Strains of Pathogenic Bacteria in Polymicrobial...

Daniel Carlson - September 7, 2021

Front Page

ParkerVision Secures Patent License and Settlement Agreement with Zyxel

Daniel Carlson - September 7, 2021

Anixa

A September To Remember?

Daniel Carlson - September 4, 2021

Front Page

LexaGene’s MiQLab(TM) System Featured at Three Key Veterinary Tradeshows

Daniel Carlson - September 3, 2021

Front Page

Lantern Pharma Expands Management Team with Appointment of Two Leading Industry...

Daniel Carlson - September 2, 2021

Front Page

Alzheimer’s Patients Treated with INmune Bio’s XPro™ Show Reduction in CSF...

Daniel Carlson - September 1, 2021

Front Page

FDA Grants Lantern Pharma Additional Orphan Drug Designation for Drug Candidate...

Daniel Carlson - August 30, 2021

Anixa

Anixa Biosciences and Moffitt Cancer Center Announce FDA Clearance to Initiate...

Daniel Carlson - August 30, 2021

Front Page

Small Caps Rebound…August Recap

Daniel Carlson - August 28, 2021

Front Page

INKmune Induces Memory-Like NK Cells…This Is A Very Big Deal

Daniel Carlson - August 26, 2021

Anixa

Anixa Biosciences’ Covid-19 Compounds Expected to be Effective Against the Delta...

Daniel Carlson - August 25, 2021

Amryt

Old Fashioned Sunday

Daniel Carlson - August 21, 2021

Front Page

PERFORMANT FINANCIAL CORPORATION ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Daniel Carlson - August 19, 2021

Front Page

Lantern Pharma Announces Positive Preclinical Data in Glioblastoma (GBM) with Drug...

Daniel Carlson - August 19, 2021

Front Page

Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society...

Daniel Carlson - August 19, 2021

Front Page

INKmune: An Interview With INmune Bio’s Dr. Mark Lowdell

Daniel Carlson - August 18, 2021

Front Page

QUEST RESOURCE HOLDING CORPORATION REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS

Daniel Carlson - August 18, 2021

Anixa

Anixa Biosciences Announces Issuance of U.S. Patent for Ovarian Cancer Vaccine...

Daniel Carlson - August 18, 2021

Front Page

Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Pancreatic Cancers...

Daniel Carlson - August 16, 2021

Front Page

Summer Stocks

Daniel Carlson - August 14, 2021

Front Page

TFF Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business...

Daniel Carlson - August 12, 2021

Front Page

LexaGene Demonstrates a Simple and Inexpensive Multiplex PCR Chemistry with Shorter...

Daniel Carlson - August 12, 2021

Front Page

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184...

Daniel Carlson - August 11, 2021

Performant

PERFORMANT FINANCIAL CORPORATION ANNOUNCES FINANCIAL RESULTS FOR SECOND QUARTER 2021

Daniel Carlson - August 10, 2021

Amryt

My Saturday Rant…

Daniel Carlson - August 7, 2021

Front Page

Trading Blog, August 6, 2021

Daniel Carlson - August 6, 2021

Amryt

Amryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance

Daniel Carlson - August 6, 2021

Front Page

INmune Bio, Inc. Announces Second Quarter 2021 Results and Provides Business...

Daniel Carlson - August 4, 2021

Front Page

FDA Grants Breakthrough Device Designation Status for Hancock Jaffe’s VenoValve

Daniel Carlson - August 3, 2021

Amryt

Are We Having Fun Yet? Bull Ride Continues

Daniel Carlson - July 31, 2021

Front Page

Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating...

Daniel Carlson - July 29, 2021

Front Page

INmune Bio, Inc. Announces Design of Upcoming Phase 2 Alzheimer’s Disease...

Daniel Carlson - July 26, 2021

Anixa

July About to Close With a Bang?

Daniel Carlson - July 24, 2021

Front Page

ParkerVision Receives Second Favorable Markman Ruling in ParkerVision v. Intel

Daniel Carlson - July 23, 2021

Front Page

Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With...

Daniel Carlson - July 20, 2021

Front Page

INmune Bio, Inc. Announces Poster Presentation and Plenary Talk at the...

Daniel Carlson - July 19, 2021

Anixa

Back In The Torture Chamber

Daniel Carlson - July 17, 2021

Front Page

INmune Bio, Inc. Announces $40 Million Registered Direct Offering

Daniel Carlson - July 14, 2021

Front Page

TFF Pharmaceuticals Announces Completion of Enrollment and Preliminary Data from its...

Daniel Carlson - July 13, 2021

Front Page

INmune Bio, Inc. Announces First Patient Treated with NK cell priming...

Daniel Carlson - July 12, 2021

Front Page

Kentucky Bluegrass

Daniel Carlson - July 10, 2021

Front Page

LexaGene Launches 2nd Generation Bacterial and Drug Resistance Test to Better...

Daniel Carlson - July 7, 2021

Anixa

Let’s Get Ready To Rumble (2nd Half Preview)

Daniel Carlson - July 3, 2021

Front Page

LexaGene Advances Towards FDA Emergency Use Authorization

Daniel Carlson - July 2, 2021

Fortress Bio

Journey Medical Corporation Enters into a Definitive Agreement with Dr. Reddy’s...

Daniel Carlson - June 30, 2021

Amryt

Hoping for Fireworks

Daniel Carlson - June 26, 2021

Front Page

Trading Blog, June 24, 2021

Daniel Carlson - June 24, 2021

Front Page

Augmenta Bioworks and TFF Pharmaceuticals Announce Selection of Lead Monoclonal Antibody...

Daniel Carlson - June 22, 2021

Front Page

Put The Hammer Down…Backgammon Lessons

Daniel Carlson - June 19, 2021

Front Page

LexaGene’s MiQLab Offers Rapid Plague Detection for Bioterrorism Threats

Daniel Carlson - June 17, 2021

Front Page

Warrant Repo Is A Coup For INmune

Daniel Carlson - June 15, 2021

Front Page

INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor...

Daniel Carlson - June 15, 2021

Front Page

QUEST RESOURCE HOLDING CORPORATION ANNOUNCES DEFINITIVE AGREEMENT TO ACQUIRE ASSET-LIGHT WASTE...

Daniel Carlson - June 15, 2021

Front Page

LexaGene Closes Sale to Alpine Veterinary Hospital

Daniel Carlson - June 14, 2021

Amryt

Stock Picking Wins This Week

Daniel Carlson - June 12, 2021

Fortress Bio

Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and...

Daniel Carlson - June 11, 2021

$Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia$

Fortress Bio